ArriVent BioPharma is a clinical-stage biopharma company developing cancer treatments, with no approved products outside China. Its lead asset is firmonertinib, an oral, once-daily EGFR mutant-selective tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. ArriVent in-licensed firmonertinib from Shanghai Allist Pharmaceuticals, which already sells the drug in China, and holds ex-China rights to develop and commercialize it. ArriVent's primary focus is two underserved mutation subsets: exon 20 insertion mutations and PACC mutations, which together account for roughly 22% of all EGFR-mutated NSCLC patients and currently lack approved oral TKI options. Firmonertinib is in two pivotal Phase 3 trials — FURVENT (exon 20 insertions, topline data expected mid-2026) and ALPACCA (PACC mutations, recently initiated) — both comparing firmonertinib to existing standards of care. Beyond firmonertinib, ArriVent has an earlier-stage ADC pipeline, also in-licensed from Chinese biotechs, targeting gastrointestinal and other cancers. ArriVent's business model follows the classic clinical-stage biopharma approach: in-license drug candidates from Chinese companies, fund development through investor capital, and pursue FDA approval to enable future drug sales. Under its Allist license, ArriVent owes milestone payments and tiered royalties on net sales if firmonertinib is commercialized.